ストックスクリーナーアプリを入手
5.36
5.65%
0.23
アフターアワーズ：
5.42
0.06
+1.12%
Turn Therapeutics Inc (TTRX) 最新ニュース
TTRX Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates as Pre-Revenue Biotech Advances Pipeline - Newser
Turn Therapeutics (TTRX) Q1 2026 Earnings: Narrow EPS Miss Amid Modest Stock GainsProfit Guidance Range - Newser
Turn Therapeutics (TTRX) Stock Trend: +2.10% Higher, $5.11 the Next Hurdle 2026-05-21Pro Trader Picks - Newser
Turn Therapeutics to Present GX-03 Atopic Dermatitis Therapy Updates at Jefferies Global Healthcare Conference 2026 12 - Minichart
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 - pharmiweb.com
Turn Therapeutics CEO to Present at Jefferies Conference - TipRanks
Turn Therapeutics to Present at Jefferies Global Healthcare Conference June 4 - TradingView
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen Hahn to Lead Clinical and Regulatory Strategy for GX-03 Atopic Dermatitis Therapy 1 - Minichart
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03 - TipRanks
Turn Therapeutics Recruits Former FDA Commissioner Stephen Hahn to Guide Eczema Drug Development - citybiz
Turn Therapeutics appoints former FDA chief Stephen Hahn - Investing.com
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead - Weekly Voice
Turn Therapeutics appoints former FDA chief Stephen Hahn By Investing.com - Investing.com Canada
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Turn Therapeutics (TTRX) Stock: Up +1.25%, Key Resistance at $4.26 2026-05-14Mid Cap Momentum - newser.com
Turn Therapeutics (Direct Listing) (TTRX) Earnings Calendar_Earnings Analysis_Financial Report and Earnings Call - Tiger Brokers
Turn Therapeutics Reports First Quarter 2026 Financial Results - TradingView
Turn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates - standard-journal.com
The key trends fueling Turn Therapeutics (TTRX) growth potential (-2.37%) 2026-05-11Elite Trading Signals - newser.com
Why Turn Therapeutics (TTRX) earnings always move the needle |Real-time Trade Ideas - newser.com
Is Turn Therapeutics (TTRX) stock changing direction |Product Revenue - Newser
TTRX Price Today: Turn Therapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Turn Therapeutics (NASDAQ:TTRX) Trading 6% HigherShould You Buy? - MarketBeat
When Will Vera Therapeutics, Inc. (NASDAQ:VERA) Turn A Profit? - 富途牛牛
TTRX (Turn Therapeutics) CEO set to share wound care pipeline outlook alongside its upcoming quarterly earnings report.Trading Community - newser.com
Is Turn Therapeutics (TTRX) Stock a future winner | Price at $3.38, Down 3.70%Verified Signals - Newser
What are bearish arguments for Turn Therapeutics (TTRX) Stock | Price at $3.43, Down 2.00%Hedge Fund Favorites - Newser
Bradley Burnam holds 52.76% of Turn Therapeutics (NASDAQ: TTRX) common stock - Stock Titan
Is Turn Therapeutics (TTRX) Stock Overvalued Now | Price at $3.36, Up 0.30%Viral Trade Signals - Newser
Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX) - Defense World
Athersys and Turn Therapeutics Battle for Biotech Supremacy - National Today
Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M - Stock Titan
Director at Turn Therapeutics (TTRX) makes bona fide gift of 300,000 shares - Stock Titan
Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike - Stock Titan
80K options granted at $3.12 to Turn Therapeutics (TTRX) - Stock Titan
TTRX Stock Analysis: Turn Therapeutics Inc at 3.35 USD post 7.54 percent daily gain - Newser
[EFFECT] Turn Therapeutics Inc. SEC Filing - Stock Titan
Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates - BioSpace
Turn Therapeutics (TTRX) registers up to 7,000,000 shares for GEM resale - Stock Titan
Turn Therapeutics (TTRX) registers 17.87M shares for resale by stockholders - Stock Titan
Turn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Turn Therapeutics (TTRX) details eczema drug plans and going-concern risk - Stock Titan
Turn Therapeutics (NASDAQ: TTRX) widens 2025 loss but secures $25M growth capital - Stock Titan
Turn Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
TTRX SEC FilingsTurn Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Turn Therapeutics Secures Up to $25 Million Financing from Avenue Capital to Advance Atopic Dermatitis and Onychomycosis Programs - Minichart
Turn Therapeutics secures up to $25M in financing from Avenue Capital Group - MSN
D. Boral Capital Reaffirms Buy Rating for Turn Therapeutics (NASDAQ:TTRX) - MarketBeat
TTRX Maintains 'Buy' Rating with $8.00 Price TargetLatest Ana - GuruFocus
Turn Therapeutics Secures Growth Capital to Advance Dermatology - tipranks.com
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group - PharmiWeb.com
1.49%
0.12%
大文字化:
|
ボリューム (24 時間):